Zaki A Sherif1,2, Armana Saeed3, Shima Ghavimi4,5, Seyed-Mehdi Nouraie4,5, Adeyinka O Laiyemo4,6,5, Hassan Brim7,3,8, Hassan Ashktorab4,3,5. 1. Department of Biochemistry and Molecular Biology, Howard University, 520 W Street NW, Washington, DC, 20059, USA. zaki.sherif@howard.edu. 2. College of Medicine, Howard University, Washington, DC, USA. zaki.sherif@howard.edu. 3. Cancer Center, Howard University, Washington, DC, USA. 4. Department of Medicine, Howard University, Washington, DC, USA. 5. Howard University Hospital, Howard University, Washington, DC, USA. 6. Division of Gastroenterology, Howard University, Washington, DC, USA. 7. Department of Pathology, Howard University, Washington, DC, USA. 8. College of Medicine, Howard University, Washington, DC, USA.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a clinical syndrome predicted to be the next global epidemic affecting millions of people worldwide. The natural course of this disease including its subtype, non-alcoholic steatohepatitis (NASH), is not clearly defined especially in the African-American segment of the US population. AIMS: To conduct a review of the global epidemiology of NAFLD with emphasis on US minority populations. METHODS: A thorough search of evidence-based literature was conducted using the Pubmed database and commercial web sources such as Medscape and Google Scholar. RESULTS: NAFLD and its subtype NASH are becoming the principal cause of chronic liver disease across the world. In the US, Hispanics are the most disproportionately affected ethnic group with hepatic steatosis, and elevated aminotransferase levels, whereas African-Americans are the least affected. Genetic disparities involved in lipid metabolism seem to be the leading explanation for the lowest incidence and prevalence of both NAFLD and NASH in African-Americans. CONCLUSIONS: The unprecedented rise in the prevalence of NAFLD globally requires an initiation of population cohort studies with long-term follow-up to determine the incidence and natural history of NAFLD and its underrepresentation in African-Americans. Future studies should also focus on the delineation of the interplay between genetic and environmental factors that trigger the development of NAFLD and NASH.
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is a clinical syndrome predicted to be the next global epidemic affecting millions of people worldwide. The natural course of this disease including its subtype, non-alcoholic steatohepatitis (NASH), is not clearly defined especially in the African-American segment of the US population. AIMS: To conduct a review of the global epidemiology of NAFLD with emphasis on US minority populations. METHODS: A thorough search of evidence-based literature was conducted using the Pubmed database and commercial web sources such as Medscape and Google Scholar. RESULTS: NAFLD and its subtype NASH are becoming the principal cause of chronic liver disease across the world. In the US, Hispanics are the most disproportionately affected ethnic group with hepatic steatosis, and elevated aminotransferase levels, whereas African-Americans are the least affected. Genetic disparities involved in lipid metabolism seem to be the leading explanation for the lowest incidence and prevalence of both NAFLD and NASH in African-Americans. CONCLUSIONS: The unprecedented rise in the prevalence of NAFLD globally requires an initiation of population cohort studies with long-term follow-up to determine the incidence and natural history of NAFLD and its underrepresentation in African-Americans. Future studies should also focus on the delineation of the interplay between genetic and environmental factors that trigger the development of NAFLD and NASH.
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: Sahil Mittal; Hashem B El-Serag; Yvonne H Sada; Fasiha Kanwal; Zhigang Duan; Sarah Temple; Sarah B May; Jennifer R Kramer; Peter A Richardson; Jessica A Davila Journal: Clin Gastroenterol Hepatol Date: 2015-07-18 Impact factor: 11.382
Authors: Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark Journal: Am J Epidemiol Date: 2013-05-23 Impact factor: 4.897
Authors: Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh Journal: Br J Radiol Date: 2018-08-29 Impact factor: 3.039
Authors: Meera Sangaramoorthy; Juan Yang; Mindy C DeRouen; Chanda Ho; Ma Somsouk; Michele M Tana; Caroline A Thompson; Joseph Gibbons; Scarlett Lin Gomez; Salma Shariff-Marco Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-11-12 Impact factor: 4.254